Skip to main content
. 2021 Nov 27;9(12):1402. doi: 10.3390/vaccines9121402

Table 1.

Age and gender of the first study group participants (n = 120).

Age Range Number Percentage (%)
<30 21 17.5
30–39 18 15.0
40–49 37 30.8
50–59 36 30.0
≥60 8 6.7
Gender Number Percentage (%)
male 18 15.0
female 102 85.0